ScreenerHero

ONCOZOncoZenge AB (publ)

STO · SE · Healthcare · Biotechnology · oncozenge.com
6.190SEK+5.81%Mkt Cap: 9.70M $P/E: —

OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Swe…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap9.70M $
Enterprise Value8.49M $
Revenue (TTM)6.79K $
Gross Profit6.79K $
Net Income (TTM)-1.52M $
Revenue/Share0.0006 USD
Last Price6.190 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-29.20
PEG—
EV/EBITDA—
EV/Revenue1249.95
P/S1347.55
P/B233.60
EPS (TTM)-1.85
EPS (Forward)-0.20
52W Range
4.51529% of range10.28
52W High10.28 SEK
52W Low4.515 SEK
Profitability
Gross Margin100.00%
Oper. Margin-31877.47%
EBITDA Margin0.00%
Profit Margin-598.35%
ROE-188.04%
ROA-65.33%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.25M $
CapEx (TTM)—
FCF Margin-17859.86%
FCF Yield-12.50%
Net Debt627.96K $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.88
Current Ratio1.26
Quick Ratio0.69
Book Value/Sh0.0250 SEK
Cash/Share0.0670 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)11.50 SEK
Upside (mean)+85.8%
Target Range11.50 SEK – 11.50 SEK
# Analysts1
Ownership
Shares Out.16.38M
Float4.92M
Insiders55.43%
Institutions15.55%
Technical
SMA 506.871 (-9.9%)
SMA 2006.254 (-1.0%)
Beta1.33
S&P 52W Chg18.16%
Avg Vol (30d)17.46K
Avg Vol (10d)24.28K
Technical Indicators
RSI (14)45.7
MACD-0.2419
MACD Signal-0.2284
MACD Hist.-0.0135
BB Upper7.163 SEK
BB Middle6.359 SEK
BB Lower5.556 SEK
BB Width25.28%
ATR (14)0.4271 SEK
Vol Ratio (20d)1.86x